Recommendations for the management of drug–drug interactions between the COVID‐19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications
C Marzolini, DR Kuritzkes, F Marra… - Clinical …, 2022 - Wiley Online Library
The coronavirus disease 2019 (COVID‐19) antiviral nirmatrelvir/ritonavir (Paxlovid) has
been granted authorization or approval in several countries for the treatment of patients with …
been granted authorization or approval in several countries for the treatment of patients with …
[HTML][HTML] Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet …
Executive summary Inspired by unprecedented improvements in human health and
development in recent decades, our world has embarked on a quest that only a generation …
development in recent decades, our world has embarked on a quest that only a generation …
[HTML][HTML] Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV
JV Lazarus, K Safreed-Harmon… - Nature …, 2021 - nature.com
Health systems have improved their abilities to identify, diagnose, treat and, increasingly,
achieve viral suppression among people living with HIV (PLHIV). Despite these advances, a …
achieve viral suppression among people living with HIV (PLHIV). Despite these advances, a …
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
JE Gallant, S Staszewski, AL Pozniak, E DeJesus… - Jama, 2004 - jamanetwork.com
ContextTenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse
transcriptase inhibitor. ObjectiveTo evaluate the efficacy and safety of tenofovir DF …
transcriptase inhibitor. ObjectiveTo evaluate the efficacy and safety of tenofovir DF …
[HTML][HTML] Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant, E DeJesus, JR Arribas… - … England Journal of …, 2006 - Mass Medical Soc
Background Durable suppression of replication of the human immunodeficiency virus (HIV)
depends on the use of potent, well-tolerated antiretroviral regimens to which patients can …
depends on the use of potent, well-tolerated antiretroviral regimens to which patients can …
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
G Fätkenheuer, AL Pozniak, MA Johnson… - Nature medicine, 2005 - nature.com
We assessed the efficacy and safety of 10-d monotherapy with the orally administered
CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of …
CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of …
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non …
P Cahn, AL Pozniak, H Mingrone, A Shuldyakov… - The Lancet, 2013 - thelancet.com
Summary Background Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has
shown potent antiviral response and a favourable safety profile. We evaluated safety …
shown potent antiviral response and a favourable safety profile. We evaluated safety …
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two …
Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to
high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug …
high plasma tenofovir concentrations. Tenofovir alafenamide is a novel tenofovir prodrug …
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization …
MD Simek, W Rida, FH Priddy, P Pung… - Journal of …, 2009 - Am Soc Microbiol
The development of a rapid and efficient system to identify human immunodeficiency virus
type 1 (HIV-1)-infected individuals with broad and potent HIV-1-specific neutralizing …
type 1 (HIV-1)-infected individuals with broad and potent HIV-1-specific neutralizing …
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
GL Dean, SG Edwards, NJ Ives, G Matthews, EF Fox… - Aids, 2002 - journals.lww.com
Treatment of tuberculosis in HIV-infected persons in the era... : AIDS Treatment of tuberculosis
in HIV-infected persons in the era of highly active antiretroviral therapy : AIDS Log in or Register …
in HIV-infected persons in the era of highly active antiretroviral therapy : AIDS Log in or Register …